Skip to main content

Grafa News and Videos — Page 275

Grafa Headlines

Grafa
Health

GRAIL shares surge after FDA reviewers raise no major concerns on Galleri cancer test

GRAIL (NASDAQ:GRAL) shares rose sharply after U.S. Food and Drug Administration staff reviewers reported no major concerns regarding the safety and analytical performance of the company’s Galleri blood test designed to detect multiple cancers.

Read more: GRAIL shares surge after FDA reviewers raise no major concerns on Galleri cancer test

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift